Although the recombinant human CTGF (100 ng/ml) caused the increase of TNFR1 expression in all the treated cancer cells, the precedent treatment with anti-TNFR1 monoclonal antibody (10 μg/ml) more profoundly prevented the increase of CTGF-induced TNFR1 expression in the CTGF-highly expressed cells (over-CTGF-HMLER and HMLER-snail) than that in the CTGF-lowly expressed cells (control-HMLER and shCTGF2) (Figure 8A–8B). Here, TNFRSF1A is linked to cancer.